Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
The company was founded in 2020 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Ryan Saadi |
Contact Details
Address: 15 Independence Boulevard, Suite #410 Warren, New Jersey 07059 United States | |
| Phone | 877-838-6436 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer and Chairman |
| Kirti Desai CPA | Chief Financial Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global Research & Development Lead |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Mittul Mehta | Chief Information Officer and Head of Tevogen.ai |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
| Sadiq Khan M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 424B3 | Prospectus |
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 26, 2024 | 424B3 | Prospectus |
| Aug 26, 2024 | 8-K/A | [Amend] Current report |
| Aug 23, 2024 | 424B3 | Prospectus |
| Aug 23, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 424B3 | Prospectus |